

Products & Programs:

UPDATE: Notice of changes to the AIM Small Joint Surgery 3
Guideline

Pharmacy:

Site of care medical necessity reviews for long-acting colony- 4
stimulating factors begin June 1, 2021

Designated specialty pharmacy network 5

Certain HIV medication combinations may require prior 6
authorization

Specialty pharmacy updates 8

Administrative:

New utilization management tool now available on Availity. 11
Payer Spaces: Authorization Rules Lookup tool

Medical attachment capability now includes itemized bills and 12
more

Coverage for PFAS and PFC blood tests for New Hampshire 15
residents

Medicare:

New provider directory indicator for telehealth services 16

Medical policies and clinical utilization management guidelines. 16
update

Access to more claim denial information is now self-service 20

Keep up with Medicare news 21

Anthem Blue Cross and Blue Shield is the trade name of: In Colorado Rocky Mountain Hospital and Medical Service, Inc. HMO products underwritten by HMO Colorado, Inc. In Connecticut: Anthem Health Plans, Inc. In Georgia: Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. In Indiana: Anthem Insurance Companies, Inc. In Kentucky: Anthem Health Plans of Kentucky, Inc. In Maine: Anthem Health Plans of Maine, Inc. In Missouri (excluding 30 counties in the Kansas City area): RightCHOICE® Managed Care, Inc. (RIT), Healthy Alliance® Life Insurance Company (HALIC), and HMO Missouri, Inc. RIT and certain affiliates administer non-HMO benefits underwritten by HALIC and HMO benefits underwritten by HMO Missouri, Inc. RIT and certain affiliates only provide administrative services for self-funded plans and do not underwrite benefits. In Nevada: Rocky Mountain Hospital and Medical Service, Inc. HMO products underwritten by HMO Colorado, Inc. dba HMO Nevada. In New Hampshire: Anthem Health Plans of New Hampshire, Inc. HMO plans are administered by Anthem Health Plans of New Hampshire, Inc. and underwritten by

Matthew Thornton Health Plan, Inc. In Ohio: Community Insurance Company. In Virginia: Anthem Health Plans of Virginia, Inc. trades as Anthem Blue Cross and Blue Shield in Virginia, and its service area is all of Virginia except for the City of Fairfax, the Town of Vienna, and the area east of State Route 123. In Wisconsin: Blue Cross Blue Shield of Wisconsin (BCBSWI), which underwrites or administers the PPO and indemnity policies and underwrites the out of network benefits in POS policies offered by Compcare or WCIC; Compcare Health Services Insurance Corporation (Compcare) underwrites or administers the HMO policies and Wisconsin Collaborative Insurance Company (WCIC) underwrites or administers Well Priority HMO or POS policies. Independent licensees of the Blue Cross and Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. The Blue Cross and Blue Shield names and symbols are registered marks of the Blue Cross and Blue Shield Association. Use of the Anthem websites constitutes your agreement with our Terms of Use.

UPDATE: Notice of changes to the AIM Small Joint Surgery Guideline

Published: Mar 1, 2021 - Products & Programs

On November 1, 2020, AIM Specialty Health® (AIM) began administering the AIM Musculoskeletal program to perform medical necessity reviews for certain elective surgeries of the small joints using AIM clinical guidelines for Anthem fully-insured members and certain ASO groups.

Effective March 14, 2021, the [AIM Small Joint Surgery Guideline](#) will be updated with the following:

- Clarified requirements for imaging reports
- Removed radiographic requirement for confirmation of lesser toe deformities
- Added ankle arthrodesis and total ankle arthroplasty as new indications for revision of failed previous reconstructions
- Removed total ankle arthroplasty requirements for adjacent joint or inflammatory arthritis
- Clarified contraindications only apply to total ankle arthroplasty

Providers should continue to submit pre-service review requests to AIM using one of the following options:

- Access AIM's **ProviderPortal**_{SM} directly at www.providerportal.com. Real-time, online access is available 24/7 to process orders, and is the fastest and most convenient way to request authorization.
- Access AIM via the Availity Portal at www.availity.com.
- Call the AIM toll-free number at 866-714-1107, Monday through Friday 8:30 a.m. – 7:00 p.m.

For questions, please contact the provider number on the back of the member's ID card.

993-0321-PN-NE

Site of care medical necessity reviews for long-acting colony-stimulating factors begin June 1, 2021

Published: Mar 1, 2021 - **Products & Programs** / Pharmacy

We are committed to being a valued health care partner in identifying ways to achieve better health outcomes, lower costs and deliver access to a better healthcare experience for consumers.

Effective with dates of service on or after June 1, 2021, medical necessity review of the site of care will be required for the following long-acting, colony-stimulating factors for oncology indications for Anthem Commercial plan members:

- Neulasta® & Neulasta Onpro® (pegfilgrastim)
- Fulphila® (pegfilgrastim-jmdb)
- Udenyca® (pegfilgrastim-cbqv)
- Ziextenzo® (pegfilgrastim-bmez)
- Nyvepria™ (pegfilgrastim-apgf)

The review will be administered by AIM Specialty Health® (AIM), a separate company.

AIM will evaluate the clinical information in the request to the *CG-MED-083 Site of Care: Specialty Pharmaceuticals* policy to determine if the hospital-based outpatient setting is medically necessary for the medication administration. To see the clinical guideline and what clinical considerations are taken into account for determination, visit our [Medical Policy and Clinical Guidelines webpage](#). You may contact AIM to request a peer-to-peer discussion before or after the determination.

The site of care medical necessity review only applies to administration performed in an outpatient hospital setting. This does not apply to requests for review of medication administration performed in a non-hospital setting or as part of an inpatient stay. Reviews also do not apply when Anthem is the secondary payer.

Submit a request for review

Starting May 16, 2021, ordering providers may submit prior authorization requests for the hospital outpatient site of care for these medications for dates of service on or after June 1, 2021 to AIM in one of the following ways:

- Access AIM *ProviderPortal*_{SM} directly at providerportal.com. Online access is available 24/7 to process orders in real-time, and is the fastest and most convenient way to request authorization.
- Access AIM via the Availity Web Portal at availability.com.
- Call the AIM Contact Center toll-free number: 866-714-1107, Monday - Friday, 8:00 a.m. - 5:00 p.m.

Please note, this review does not apply to the following plans: BlueCard[®], Federal Employee Program[®] (FEP[®]), Medicaid, Medicare Advantage and Medicare Supplemental plans. Providers can view prior authorization requirements for Anthem members on the [Clinical Criteria webpage](#).

Providers should continue to verify eligibility and benefits for all members prior to rendering services.

If you have questions, please call the Provider Service phone number on the member's ID card.

1019-0321-PN-NE

URL: <https://providernews.anthem.com/new-hampshire/article/site-of-care-medical-necessity-reviews-for-long-acting-colony-stimulating-factors-begin-june-1-2021-5>

Designated specialty pharmacy network

Published: Mar 1, 2021 - **Products & Programs** / Pharmacy

Beginning June 1, 2021, Anthem Blue Cross and Blue Shield (Anthem) is implementing a designated network for select specialty pharmacy medications administered in the outpatient hospital setting ("Designated SRx Network"). This applies to all Anthem commercial members and claims priced by Anthem for commercial BlueCard Program members. This

Hospitals that are **not** in our Designated SRx Network will be required to acquire the select specialty pharmacy medications administered in the hospital outpatient setting through CVS Specialty Pharmacy. **For dates of service on or after June 1, 2021**, the prescribing provider for Anthem commercial members should continue to contact AIM Specialty Health or IngenioRx for prior authorization. During the authorization process, the prescribing provider will be notified of the requirement to utilize CVS Specialty as the dispensing provider for the specialty pharmacy medication when administered in the outpatient hospital setting. The failure to do so will result in claim denials and the member cannot be billed for these specialty medications. Hospitals may continue to submit a claim for administration of the specialty pharmacy medications in the outpatient hospital setting, which will be reimbursed at the current contracted rates.

If you wish to be included in the Designated SRx Network by agreeing to the terms/conditions, please contact your Anthem facility contract manager.

The list of specialty pharmacy medications subject to the above will be posted at anthem.com for reference and is subject to change. All specialty pharmacy prior authorization requirements will still apply and are the responsibility of the prescribing provider.

This will have no impact on how members obtain non-specialty pharmacy medications at retail pharmacies or by mail-order.

To access the current [Designated Medical Specialty Pharmacy Drug List](#), visit anthem.com, select *Providers*, select *New Hampshire* (top right of page), select *Forms and Guides* (under the *Provider Resources* column). Scroll down and select *Pharmacy* in the Category drop down.

1004-0321-PN-NH

URL: <https://providernews.anthem.com/new-hampshire/article/designated-specialty-pharmacy-network-2>

Certain HIV medication combinations may require prior authorization

Published: Mar 1, 2021 - **Products & Programs** / Pharmacy

Effective May 1, 2021, we will implement a new prior authorization requirement for HIV medications to help ensure patients are not receiving therapeutic duplications when taking certain combinations. Providers and members expected to be impacted by this new prior authorization requirement will receive advanced notice by mail.

In order for members to continue to receive coverage for the drug combination, providers must submit a separate prior authorization form for each drug and provide the medical necessity rationale for why the drug combination is clinically necessary.

Combinations that are considered clinical duplicates are based on drug mechanism of action (MOA) and developed in accordance with the U.S. Department of Health and Human Services HIV Guidelines.

The duplicate therapy policy may be initiated as a result of one of the following drug combinations:

Duplicate Name	Duplicate Description	Example
Integrase stand transfer inhibitors (INSTI)	Two drug products each containing a drug with an INSTI mechanism of action	Isentress (raltegravir) and Dovato (dolutegravir/lamivudine)
Non-nucleoside reverse transcriptase inhibitors (NNRTI)	Two drug products each containing a drug with an NNRTI mechanism of action.	Edurant (rilpivirine) and Symfi (efavirenz/lamivudine/TDF)
Protease inhibitors (PI)	Two drug products each containing a drug with a PI mechanism of action	Prezcobix (darunavir/cobicistat) and Reyataz (atazanavir)
Nucleoside reverse transcriptase inhibitors (NRTI)	Two drug products that together result in four NRTI active ingredients	Truvada (emtricitabine/TDF) and Biktarvy (bictegravir/emtricitabine/TAF)
Boosters	Two drug products that result in a combination of the protease inhibitor boosters, ritonavir and cobicistat	Prezcobix (darunavir/cobicistat) and Kaletra (lopinavir/ritonavir)

As a reminder, prior authorizations may be submitted via phone, fax, or online (through www.CoverMyMeds.com). If you have questions, please call the Provider Service phone number on the member's ID card.

1002-0321-PN-NE

URL: <https://providernews.anthem.com/new-hampshire/article/certain-hiv-medication-combinations-may-require-prior-authorization>

Specialty pharmacy updates

Published: Mar 1, 2021 - **Products & Programs** / Pharmacy

Prior authorization updates

Effective for dates of service on and after June 1, 2021, the following specialty pharmacy codes from current or new clinical criteria documents will be included in our prior authorization review process.

Please note, inclusion of national drug code (NDC) code on your claim will help expedite claim processing of drugs billed with a not otherwise classified (NOC) code.

Visit our website to access the [clinical criteria information](#).

Clinical Criteria	HCPCS or CPT Code(s)	Drug
*ING-CC-0185	J3490, C9399	Oxlumo
**ING-CC-0184	J3490, J3590, J9999	Danyelza

*Prior authorization clinical review of **non-oncology** use of specialty pharmacy drugs is managed by the medical specialty drug review team.

Review of specialty pharmacy drugs for **oncology use is managed by AIM Specialty Health® (AIM).

Prior authorization update – change in effective date

Please note the change in date for the implementation of prior authorization for the injectable iron deficiency anemia products listed below. The effective date previously communicated was March 1, 2021.

Effective for dates of service on and after May 1, 2021, the following specialty pharmacy codes from current or new clinical criteria documents will be included in our prior authorization review process.

Please note, inclusion of national drug code (NDC) code on your claim will help expedite claim processing of drugs billed with a not otherwise classified (NOC) code.

Visit our website to access the [clinical criteria information](#).

Clinical Criteria	HCPCS or CPT Code	Drug
*ING-CC-0182	J1756	Venofer
*ING-CC-0182	J2916	Ferrlecit
*ING-CC-0182	J1750	Infed
*ING-CC-0182	J1439	Injectafer
*ING-CC-0182	Q0138	Feraheme
*ING-CC-0182	J1437	Monoferric

*Prior authorization clinical review of **non-oncology** use of specialty pharmacy drugs is managed by the medical specialty drug review team.

Step therapy update – change in effective date

Please note the change in date for the implementation of step therapy for the injectable iron deficiency anemia products listed below. The effective date previously communicated was March 1, 2021.

Effective for dates of service on and after May 1, 2021, the following specialty pharmacy codes from current or new clinical criteria documents will be included in our existing specialty pharmacy medical step therapy review process.

Please note, inclusion of national drug code (NDC) code on your claim will help expedite claim processing of drugs billed with a not otherwise classified (NOC) code.

Visit our website to access the [clinical criteria information](#).

Clinical Criteria	Status	Drug	HCPCS Codes
*ING-CC-0182	Preferred	Venofer	J1756
*ING-CC-0182	Preferred	Ferrlecit	J2916
*ING-CC-0182	Preferred	Infed	J1750
*ING-CC-0182	Non-preferred	Injectafer	J1439
*ING-CC-0182	Non-preferred	Feraheme	Q0138
*ING-CC-0182	Non-preferred	Monoferric	J1437

*Prior authorization clinical review of **non-oncology** specialty pharmacy drugs will be managed by the medical specialty drug review team.

Prior authorization update - codes removed from prior authorization requirement

In a recent notification, we shared that effective April 1, 2021, the following codes would be included in our prior authorization review process. Please be advised that these codes **will NOT be included in our prior authorization review process at this time.**

Clinical Criteria	HCPCS or CPT Code	Drug
ING-CC-0095	J9041	Velcade (Bortezomib)
ING-CC-0095	J9044	Bortezomib
ING-CC-0093	J9171	Docetaxel

Medical specialty pharmacy update – removal of prior authorization requirement for certain drugs used to treat ocular conditions

In an effort to help simplify care and support our providers, effective **May 1, 2021**, we have **removed the prior authorization requirement** for the use of the drugs listed below used to treat ocular conditions.

Drug	Code(s)	Code description
Avastin	C9257, J9035	Intravitreal bevacizumab
Mvasi	Q5107	Bevacizumab-awwb
Zirabev	Q5118	Bevacizumab-bvzr

1007-0321-PN-NE

URL: <https://providernews.anthem.com/new-hampshire/article/specialty-pharmacy-updates>

New utilization management tool now available on Availity Payer Spaces: Authorization Rules Lookup tool

Published: Mar 1, 2021 - Administrative

In February, we introduced our new Authorization Rules Lookup tool that you can access through Availity Payer Spaces. This new self-service application displays prior authorization rules so you can quickly verify if the outpatient services require prior authorization for members enrolled in Anthem's commercial plans.

In addition to verifying whether an outpatient authorization is needed, the tool provides the following details that apply to the procedure code:

- Medical Policies and Clinical Guidelines
- Third Party Guidelines, if applicable (such as AIM Specialty Health, IngenioRx)

Access the Authorization Lookup application through Availity Payer Spaces

Access to the tool does not require an Availity role assignment.

1. Select **Payer Spaces**
2. Select the **Anthem Blue Cross Blue Shield** tile from the Payer Spaces menu
3. Select the **Applications** tab
4. Select the **Authorization Rules Lookup** tile

Once you are in the tool, you will need to provide the following information to display the service's prior authorization rules:

- Tax ID
- National Provider Identifier (NPI)
- Member ID and birth date
- Member's group number or contract code

(This information can be found on the member's ID card or through the Eligibility & Benefits return on the Patient Information tab)

- CPT/HCPCS code

Give this new tool a try and discover how much this will improve the efficiency of your authorization process.

Please note: If a prior authorization is required for outpatient services, you may submit the case through Interactive Care Reviewer, Anthem's online authorization tool that is also accessible through the Availity Portal.

1005-0321-PN-NE

URL: <https://providernews.anthem.com/new-hampshire/article/new-utilization-management-tool-now-available-on-availity-payer-spaces-authorization-rules-lookup-tool-3>

Medical attachment capability now includes itemized bills and more

Published: Mar 1, 2021 - **Administrative**

To help ensure accuracy and eliminate delays in the adjudication of your claims, the itemized bill must be included with qualifying claim submissions. Submitting an itemized bill (unsolicited* medical attachment) for a high dollar claim just got easier!

To submit an itemized bill (unsolicited medical attachment):

1. Log in to Availity Portal
2. Select **Claims & Payments | Attachments – New**
3. Select **Send Attachment**
4. Under **Request for Information**, select **No, if you are including the supplemental information/attachment for an 837 claim PWK.** (see example below)

Request for Information

Select Yes, if you are responding to a request from the health plan or need to submit documentation for a specific claim number.

Select No, if you are including the supplemental information/attachment for an 837 claim PWK.

Yes No

1. Include provider, patient and claim information
2. Attach supporting documentation and reason (example shown below)
3. Send attachment(s)

Attach Supporting Documentation

ADDING ATTACHMENTS:

- This Health Plan supports file types including .jpeg, .jpg, .pdf, .tif and .tif.
- File names cannot contain spaces or special characters with the exception of "_" and "*".

Reason

Choose one ...

11503-0 - Medical Records

48768-6 - Itemized Bills

Providers may also submit a claim attachment using the Availity Portal for solicited** medical attachments.

To submit supporting documentation in response to a formal (solicited) request from the payer:


- Log in to Availity Portal
- Select **Claims & Payments | Attachments – New**
- Select **Send Attachment**
- Under the **Request for Information**, select **Yes, if you are responding to a request from the health plan or need to submit documentation for a specific claim number** (see example below)
- Add supporting documentation and reason
- Submit

Request for Information

Select Yes, if you are responding to a request from the health plan or need to submit documentation for a specific claim number.

Select No, if you are including the supplemental information/attachment for an 837 claim PWK.

Yes No

Documentation Type 

Other Claim Documentation Request

Quality Claims Review (QCR)

Special Investigations Unit (SIU)

Additionally, if you attended a previous webinar, we have updated information on submitting an EDI 837 batch that includes a PWK segment in loops 2300/2400. The update is regarding the linkage between the electronic claim and your supplemental documentation that can be submitted through the Availity portal.

What does this mean for you?

You may now submit attachments electronically (EDI) using the PWK segment to specify that documents are being submitted in support of the claim and no additional face sheet or coversheet is needed.

Here are the steps:

- Log in to Availity Portal
- Select **Claims & Payments | Attachments - New**
- From the **Inbox** tab, select the appropriate claim or open the request in your work queue
- Add files with supporting documentation
- Submit

Get trained

- Attend an Availity-hosted webinar to learn more about all capabilities. You can register for an upcoming live webinar hosted by Availity [here](#), **or**

- Log into [Availity.com](https://www.availity.com) and select **Help & Training | Get Trained** to open the Availity Learning Center in a new tab (it is your dedicated ALC account).
- Search by keyword (**Medattach**) to find on-demand and live training options
- Click Enroll to enroll for a course and then go to your Dashboard to access it any time

Get started today with these wide-ranging capability enhancements to transform your business operations to a quick, secure, paperless and simple process to fulfill medical records requests electronically through Availity.

*Unsolicited attachment: Documentation submitted without a formal request from the payer

**Solicited attachment: Documentation submitted in response to a specific request from payer

1017-0321-PN-NE

URL: <https://providernews.anthem.com/new-hampshire/article/medical-attachment-capability-now-includes-itemized-bills-and-more-2>

Coverage for PFAS and PFC blood tests for New Hampshire residents

Published: Mar 1, 2021 - **Administrative**

Effective September 21, 2020, Anthem provides coverage for perfluoroalkyls (PFAS) and perfluorinated compound (PFC) blood testing for members who are residents of New Hampshire. PFAS and PFC testing is available from Quest Diagnostics, Inc., with testing covered subject to the same member cost shares that would apply to other diagnostic lab services.

Providers ordering PFAS/PFC testing should use ICD-10 code Z13.88 (Encounter for screening for disorder due to exposure to contaminants) to ensure testing is covered as required by the NH mandate.

Perfluorooctanoic Acid, Blood

Quest Diagnostics test code 94088

CPT code 82542

983-0321-PN-NH

URL: <https://providernews.anthem.com/new-hampshire/article/coverage-for-pfas-and-pfc-blood-tests-for-new-hampshire-residents>

New provider directory indicator for telehealth services

Published: Mar 1, 2021 - **State & Federal** / Medicare

We will begin publishing a new indicator in our online provider directories to help members easily identify professional providers who offer telehealth services.

We encourage providers who offer telehealth services to use the online [Provider Maintenance Form](#) to notify us, and we will add a telehealth indicator to your online provider directory profile.

Please contact Provider Services with any questions.

ABSCRNU-0203-20

URL: <https://providernews.anthem.com/new-hampshire/article/new-provider-directory-indicator-for-telehealth-services-21>

Medical policies and clinical utilization management guidelines update

Published: Mar 1, 2021 - **State & Federal** / Medicare

The medical policies, clinical utilization management (UM) guidelines and third party criteria below were developed and/or revised to support clinical coding edits. Note, several policies and guidelines were revised to provide clarification only and are not included. Existing

Please share this notice with other members of your practice and office staff.

Visit our [website](#) to view our medical policies and clinical UM guidelines.

Notes/updates:

Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive.

- ***GENE.00055** – Gene Expression Profiling for Risk Stratification of Inflammatory Bowel Disease (IBD) Severity
 - Gene expression profiling for risk stratification of inflammatory bowel disease (IBD) severity, including use of PredictSURE IBD, is considered investigational and not medically necessary for all indications

- ***LAB.00037** – Serologic Testing for Biomarkers of Irritable Bowel Syndrome (IBS)
 - Serological testing for biomarkers of irritable bowel syndrome (for example, CdtB and anti-vinculin), using tests such as, IBSDetex, ibs-smart or IBSchek, is considered investigational and not medically necessary for screening, diagnosis or management of irritable bowel syndrome, and for all other indications

- ***DME.00011** – Electrical Stimulation as a Treatment for Pain and Other Conditions: Surface and Percutaneous Devices
 - Revised scope to only include non-implantable devices and moved content addressing implantable devices to SURG.00158
 - Added “non-implantable” to bullet point on percutaneous neuromodulation therapy
 - Added percutaneous electrical nerve field stimulation (PENFS) as investigational and not medically necessary for all indications

- ***SURG.00062** – Vein Embolization as a Treatment for Pelvic Congestion Syndrome and Varicocele
 - Expanded scope to include percutaneous testicular vein embolization for varicocele and added embolization of the testicular (spermatic) veins as investigational and not medically necessary as a treatment of testicular varicocele

- ***CG-LAB-15** – Red Blood Cell Folic Acid Testing
 - RBC folic acid testing is considered not medically necessary in all cases
- ***CG-LAB-16** – Serum Amylase Testing
 - Serum amylase testing is considered not medically necessary for acute and chronic pancreatitis and all other conditions
- ***CG-GENE-04** – Molecular Marker Evaluation of Thyroid Nodules
 - Added the Afirma Xpression Atlas as not medically necessary
- **00158** – Implantable Peripheral Nerve Stimulation Devices as a Treatment for Pain
 - A new medical policy was created from content contained in DME.00011.
 - There are no changes to the policy content.
 - Publish date is December 16, 2020.
- **CG-GENE-21** – Cell-Free Fetal DNA-Based Prenatal Testing
 - A new clinical guideline was created from content contained in GENE.00026.
 - There are no changes to the guideline content.
 - Publish date is December 16, 2020.

Medical policies

On November 5, 2020, the medical policy and technology assessment committee (MPTAC) approved the following medical policies applicable to Anthem. These guidelines take effect March 8, 2021.

Publish date	Medical Policy number	Medical Policy title	New or revised
12/16/2020	*GENE.00055	Gene Expression Profiling for Risk Stratification of Inflammatory Bowel Disease (IBD) Severity	New
12/16/2020	*LAB.00037	Serologic Testing for Biomarkers of Irritable Bowel Syndrome (IBS)	New
11/12/2020	ANC.00009	Cosmetic and Reconstructive Services of the Trunk and Groin	Revised
12/16/2020	*DME.00011	Electrical Stimulation as a Treatment for Pain and Other Conditions: Surface and Percutaneous Devices	Revised
11/12/2020	GENE.00052	Whole Genome Sequencing, Whole Exome Sequencing, Gene Panels, and Molecular Profiling	Revised
11/12/2020	MED.00129	Gene Therapy for Spinal Muscular Atrophy	Revised
12/16/2020	SURG.00011	Allogeneic, Xenographic, Synthetic and Composite Products for Wound Healing and Soft Tissue Grafting	Revised
12/16/2020	*SURG.00062	Vein Embolization as a Treatment for Pelvic Congestion Syndrome and Varicocele	Revised

Clinical UM guidelines

On November 5, 2020, the MPTAC approved the following clinical UM guidelines applicable to Anthem. These guidelines were adopted by the medical operations committee for Anthem members on November 19, 2020. These guidelines take effect March 8, 2021.

Publish date	Clinical UM Guideline number	Clinical UM Guideline title	New or revised
12/16/2020	*CG-LAB-15	Red Blood Cell Folic Acid Testing	New
12/16/2020	*CG-LAB-16	Serum Amylase Testing	New
11/12/2020	CG-DME-42	Non-implantable Insulin Infusion and Blood Glucose Monitoring Devices	Revised
12/16/2020	*CG-GENE-04	Molecular Marker Evaluation of Thyroid Nodules	Revised
12/16/2020	CG-GENE-18	Genetic Testing for TP53 Mutations	Revised
12/16/2020	CG-GENE-20	Epidermal Growth Factor Receptor (EGFR) Testing	Revised
11/12/2020	CG-MED-87	Single Photon Emission Computed Tomography Scans for Noncardiovascular Indications	Revised

ABSCRNU-0206-21

URL: <https://providernews.anthem.com/new-hampshire/article/medical-policies-and-clinical-utilization-management-guidelines-update-me-only-for-anthem-and-amh-health-llc-1>

Access to more claim denial information is now self-service

Published: Mar 1, 2021 - **State & Federal** / Medicare

Through predictive analytics, healthcare teams can now receive real-time solutions to claim denials.

Anthem is committed to providing digital first solutions. Healthcare teams can now use self-service tools to reduce the amount of time spent following up on claim denials. Through the application of predictive analytics, Anthem has the answers before you ask the questions. With an initial focus on claim-level insights, Anthem has streamlined claim denial inquiries by making the reasons for the claim denial digitally available. In addition to the reason for the denial, we supply you with the next steps needed to move the claim to payment. This eliminates the need to call for updates and experience any unnecessary delays waiting for the Explanation of Payment (EOP).

Access the *Claims Status Listing* on Payer Spaces from <https://www.anthem.com/medicareprovider> using the Log In button or through the secure provider portal via *Availity**. We provide a complete list of claims, highlight those claims that have proactive insights, provide a reason for the denial, and the information needed to move the claim forward.

Claim resolution daily

Automated updates make it possible to refresh claims history daily. As you resolve claim denials, the claim status changes, other claims needing resolution are added, and claims are resolved faster.

Anthem made it easier to update and supply additional information, too. While logged into the secure provider portal, you have the ability to revise your claim, add attachments, or eliminate it if filed in error. Even if you did not file the claim digitally, you can access the proactive insights. Predictive analytics supplies the needed claim denial information online — all in one place.

Predictive proactive issue resolution and near real-time digital claim denial information is another example of how Anthem is using digital technology to improve the healthcare experience. If you have questions, please reach out to your Provider Relations representative.

ABSCRNU-0193-20

URL: <https://providernews.anthem.com/new-hampshire/article/access-to-more-claim-denial-information-is-now-self-service-12>

Keep up with Medicare news

Published: Mar 1, 2021 - **State & Federal** / Medicare

Please continue to check [Important Medicare Advantage Updates](#) at [anthem.com/medicareprovider](https://www.anthem.com/medicareprovider) for the latest Medicare Advantage information, including:

- [MCG Care Guidelines 24th edition customization for Anthem](#)
- [DME checklist of information needed from providers for Anthem members](#)

URL: <https://providernews.anthem.com/new-hampshire/article/keep-up-with-medicare-news-193>
